Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pocket-Accommodating Jeep Wrangler Buying Guide for Seniors - 2Why most Jewish Israelis back the death penalty for terrorists
- 3I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake.
- 4Police arrest 18 as anti-war protests spread across Tel Aviv, Haifa, Jerusalem
- 5Make your choice for the music application with the most amicable connection point!
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- I'm a woman who's into weightlifting. Was I man enough for the creatine-packed 'Man Cereal'?
- Why doing good also makes us feel good, during the holidays and beyond
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- Sahel coups push Africa to top of global democratic declines, report finds
- UN warns civil liberties under threat due to war in Middle East
- Israeli strikes on Beirut, as Hezbollah and Iran attack Israel
- 'Harry Potter' fans rejoice: HBO releases 1st trailer for new TV series, set to premiere this Christmas
- Hitler's madcap mega-railway would have linked Berlin with India
